These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197 [TBL] [Abstract][Full Text] [Related]
3. Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Tsai DE; Luger SM; Kemner A; Swider C; Goradia A; Tomczak E; DiPatri D; Bagg A; Nowell P; Loren AW; Perl A; Schuster S; Thompson JE; Porter D; Andreadis C; Stadtmauer EA; Goldsteini S; Ghalie R; Carroll M Cancer Biol Ther; 2007 Jan; 6(1):18-21. PubMed ID: 17204865 [TBL] [Abstract][Full Text] [Related]
4. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors. Qi L; Guo Y; Zhang P; Cao X; Luan Y Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040 [TBL] [Abstract][Full Text] [Related]
5. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. DiNardo CD; Ky B; Vogl DT; Forfia P; Loren A; Luger S; Mato A; Tsai DE Med Oncol; 2008; 25(3):299-302. PubMed ID: 18181037 [TBL] [Abstract][Full Text] [Related]
6. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma]. Drugeon C; Charlat I; Boulinguez S; Viraben R Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686 [TBL] [Abstract][Full Text] [Related]
9. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization. el-Azhary RA; Bouwhuis SA Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556 [TBL] [Abstract][Full Text] [Related]
11. The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats. Nowak B; Matuszewska A; Filipiak J; Nikodem A; Merwid-Ląd A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A Adv Med Sci; 2016 Mar; 61(1):85-9. PubMed ID: 26569440 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463 [TBL] [Abstract][Full Text] [Related]
14. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091 [TBL] [Abstract][Full Text] [Related]
15. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617 [TBL] [Abstract][Full Text] [Related]
16. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668 [TBL] [Abstract][Full Text] [Related]
17. Bexarotene: a promising anticancer agent. Qu L; Tang X Cancer Chemother Pharmacol; 2010 Jan; 65(2):201-5. PubMed ID: 19777233 [TBL] [Abstract][Full Text] [Related]
18. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520 [TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854 [TBL] [Abstract][Full Text] [Related]
20. Bexarotene reverses alopecia in cutaneous T-cell lymphoma. Hanson M; Hill A; Duvic M Br J Dermatol; 2003 Jul; 149(1):193-6. PubMed ID: 12890219 [No Abstract] [Full Text] [Related] [Next] [New Search]